Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis

被引：0
作者：
Wanruchada Katchamart
Pongthorn Narongroeknawin
Ngamsiree Sukprasert
Wanwisa Chanapai
Ananya Srisomnuek
机构：
[1] Mahidol University,Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital
[2] Phramongkutklao Hospital and College of Medicine,Division of Rheumatology, Department of Medicine
[3] Mahidol University,Department of Medicine, Faculty of Medicine Siriraj Hospital
[4] Mahidol University,Division of Clinical Trials, Research Department, Faculty of Medicine Siriraj Hospital
来源：
Clinical Rheumatology | 2021年 / 40卷
关键词：
Compliance-Questionnaire-Rheumatology; Medication compliance; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1291 / 1298
页数：7
相关论文
共 50 条
[21]   Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs [J].
Kim, Seoyoung C. ;
Solomon, Daniel H. ;
Liu, Jun ;
Franklin, Jessica M. ;
Glynn, Robert J. ;
Schneeweiss, Sebastian .
AMERICAN JOURNAL OF MEDICINE, 2015, 128 (05) :539.e7-539.e17
[22]   Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [J].
Terabe, Kenya ;
Takahashi, Nobunori ;
Asai, Shuji ;
Hirano, Yuji ;
Kanayama, Yasuhide ;
Yabe, Yuichiro ;
Oguchi, Takeshi ;
Fujibayashi, Takayoshi ;
Ishikawa, Hisato ;
Hanabayashi, Masahiro ;
Hattori, Yosuke ;
Suzuki, Mochihito ;
Kishimoto, Kenji ;
Ohashi, Yoshifumi ;
Imaizumi, Takahiro ;
Imagama, Shiro ;
Kojima, Toshihisa .
MODERN RHEUMATOLOGY, 2023, 33 (02) :292-301
[23]   Disease-Modifying Antirheumatic Drugs Increase Serum Adiponectin Levels in Patients With Rheumatoid Arthritis [J].
Cansu, Baris ;
Cansu, Dondu U. ;
Kasifoglu, Timucin ;
Gulbas, Zafer ;
Korkmaz, Cengiz .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (01) :14-17
[24]   Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis [J].
Costa, Neide Tomimura ;
Veiga Iriyoda, Tatiana Mayumi ;
Alfieri, Daniela Frizon ;
Colado Simao, Andrea Name ;
Dichi, Isaias .
INFLAMMOPHARMACOLOGY, 2018, 26 (05) :1151-1164
[25]   Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients [J].
Griffiths, RI ;
Bar-Din, M ;
MacLean, C ;
Sullivan, EM ;
Herbert, RJ ;
Yelin, EH .
THERAPEUTIC APHERESIS, 2001, 5 (02) :92-104
[26]   Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients [J].
Joo, Young Bin ;
Jung, Seung Min ;
Park, Yune-Jung ;
Kim, Ki-Jo ;
Park, Kyung-Su .
JOURNAL OF RHEUMATIC DISEASES, 2022, 29 (03) :162-170
[27]   Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA) [J].
Münster, T ;
Furst, DE .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (06) :S29-S36
[28]   Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis [J].
Grijalva, Carlos G. ;
Chung, Cecilia P. ;
Arbogast, Patrick G. ;
Stein, Charles M. ;
Mitchel, Edward F., Jr. ;
Griffin, Marie R. .
MEDICAL CARE, 2007, 45 (10) :S66-S76
[29]   Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis [J].
Neide Tomimura Costa ;
Tatiana Mayumi Veiga Iriyoda ;
Daniela Frizon Alfieri ;
Andréa Name Colado Simão ;
Isaias Dichi .
Inflammopharmacology, 2018, 26 :1151-1164
[30]   Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis [J].
Williams, HJ .
BRITISH JOURNAL OF RHEUMATOLOGY, 1995, 34 :96-99
12345